BACKGROUND & AIMS:Norfloxacin is highly effective in preventing spontaneous bacterial peritonitis recurrence in cirrhosis, but its role in the primary prevention of this complication is uncertain. METHODS:Patients with cirrhosis and low protein ascitic levels (<15 g/L) with advanced liver failure (Child-Pugh score > or = 9 points with serum bilirubin level > or = 3 mg/dL) or impaired renal function (serum creatinine level > or = 1.2 mg/dL, blood urea nitrogen level > or = 25 mg/dL, or serum sodium level < or = 130 mEq/L) were included in a randomized controlled trial aimed at comparing norfloxacin (35 patients) vs placebo (33 patients) in the primary prophylaxis of spontaneous bacterial peritonitis. The main end points of the trial were 3-month and 1-year probability of survival. Secondary end points were 1-year probability of development of spontaneous bacterial peritonitis and hepatorenal syndrome. RESULTS:Norfloxacin administration reduced the 1-year probability of developing spontaneous bacterial peritonitis (7% vs 61%, P < .001) and hepatorenal syndrome (28% vs 41%, P = .02), and improved the 3-month (94% vs 62%, P = .003) and the 1-year (60% vs 48%, P = .05) probability of survival compared with placebo. CONCLUSIONS: Primary prophylaxis with norfloxacin has a great impact in the clinical course of patients with advanced cirrhosis. It reduces the incidence of spontaneous bacterial peritonitis, delays the development of hepatorenal syndrome, and improves survival.
RCT Entities:
BACKGROUND & AIMS:Norfloxacin is highly effective in preventing spontaneous bacterial peritonitis recurrence in cirrhosis, but its role in the primary prevention of this complication is uncertain. METHODS:Patients with cirrhosis and low protein ascitic levels (<15 g/L) with advanced liver failure (Child-Pugh score > or = 9 points with serum bilirubin level > or = 3 mg/dL) or impaired renal function (serum creatinine level > or = 1.2 mg/dL, blood urea nitrogen level > or = 25 mg/dL, or serum sodium level < or = 130 mEq/L) were included in a randomized controlled trial aimed at comparing norfloxacin (35 patients) vs placebo (33 patients) in the primary prophylaxis of spontaneous bacterial peritonitis. The main end points of the trial were 3-month and 1-year probability of survival. Secondary end points were 1-year probability of development of spontaneous bacterial peritonitis and hepatorenal syndrome. RESULTS:Norfloxacin administration reduced the 1-year probability of developing spontaneous bacterial peritonitis (7% vs 61%, P < .001) and hepatorenal syndrome (28% vs 41%, P = .02), and improved the 3-month (94% vs 62%, P = .003) and the 1-year (60% vs 48%, P = .05) probability of survival compared with placebo. CONCLUSIONS: Primary prophylaxis with norfloxacin has a great impact in the clinical course of patients with advanced cirrhosis. It reduces the incidence of spontaneous bacterial peritonitis, delays the development of hepatorenal syndrome, and improves survival.
Authors: Puncho Gurung; Mark Goldblatt; John T Huggins; Peter Doelken; Paul J Nietert; Steven A Sahn Journal: Chest Date: 2011-01-27 Impact factor: 9.410
Authors: Brian Erly; William D Carey; Baljendra Kapoor; J Mark McKinney; Mathew Tam; Weiping Wang Journal: Semin Intervent Radiol Date: 2015-12 Impact factor: 1.513
Authors: Olga Baraldi; Chiara Valentini; Gabriele Donati; Giorgia Comai; Vania Cuna; Irene Capelli; Maria Laura Angelini; Maria Ilaria Moretti; Andrea Angeletti; Fabio Piscaglia; Gaetano La Manna Journal: World J Nephrol Date: 2015-11-06
Authors: Florence Wong; Jacqueline G O'Leary; K Rajender Reddy; Heather Patton; Patrick S Kamath; Michael B Fallon; Guadalupe Garcia-Tsao; Ram M Subramanian; Raza Malik; Benedict Maliakkal; Leroy R Thacker; Jasmohan S Bajaj Journal: Gastroenterology Date: 2013-08-30 Impact factor: 22.682